| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/why-immunitybio-stock-slumped-monday","as_of":"2026-04-07T01:29:17.556338+00:00","canonical_url":"https://www.fool.com/investing/2026/04/06/why-immunitybio-stock-slumped-on-monday/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-immunitybio-stock-slumped-monday","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_f155d3c869d2f27c","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/06/why-immunitybio-stock-slumped-on-monday/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-07T19:00:55.925782+00:00","extraction_method":"heuristic","fetched_description":"Key PointsIt sent the company a warning letter about a TV ad and a podcast episode about Anktiva.","fetched_title":"Why ImmunityBio Stock Slumped on Monday | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-immunitybio-stock-slumped-monday","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-immunitybio-stock-slumped-monday","source_event_id":"evt_8a526e5c79a5","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"4f08b081145a1ba9","kind":"unusual_volume","published_at":"2026-04-07T00:01:34+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["April 6, 2026"],"entities":[{"asset_class":"equity","name":"ImmunityBio","relevance":"primary","symbol":"IBRX","type":"company"}],"event_type":"price_action","information_gaps":["Exact volume ratio vs average volume is not provided.","Baseline volume data is missing."],"key_facts":["ImmunityBio's stock fell over 3% on April 6, 2026.","The FDA issued a warning letter about misleading promotional materials.","The company has taken steps to address the FDA's concerns."],"numeric_claims":[{"label":"stock decline percentage","value":"3%"}],"primary_claim":"ImmunityBio's stock declined by slightly over 3% due to an FDA warning letter about misleading promotional materials.","relevance_score":0.8,"sentiment":"negative","source_quality":"high","summary":"ImmunityBio's stock fell over 3% following a warning letter from the FDA regarding misleading promotional materials for its drug Anktiva. The company has since responded and taken steps to address the regulator's concerns.","topics":["FDA warning","stock decline","ImmunityBio","Anktiva"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsIt sent the company a warning letter about a TV ad and a podcast episode about Anktiva.","tickers":[],"title":"Why ImmunityBio Stock Slumped on Monday","url":"https://www.fool.com/investing/2026/04/06/why-immunitybio-stock-slumped-on-monday/"}... |